1 Graduate School of Guangxi University of Chinese Medicine, Nanning, China.
2 Department of Hematology, The 923rd Hospital of the Joint Logistics Support Force of the Peoples Liberation Army, Nanning, China.
3 Graduate School of Guilin Medical University, Guilin, China.
4 People's Hospital of Guiping, Guiping, China.
5 People's Hospital of Hezhou, Hezhou, China.
| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Objective: This study focused on the efficacy and safety of thalidomide for patients with β-thalassemia in a multicenter trial.
Patients and Methods
|Table 1. Laboratory data of the patients with β-thalassemia and treatment with thalidomide.|
|Figure 1. Hemoglobin levels of the patients receiving thalidomide therapy.|
|Figure 2. Hemoglobin levels of patients with drug discontinuation and adjustment of dosages. (a) Hemoglobin levels of patients with dose reduction. P1, P2, P3 and P4 indicate patients with a dose reduction from 50 mg/d to 25 mg/d. P5 and P6 signify patients with a dose reduction from 100 mg/d to 50 mg/d. (b) Hemoglobin levels of the patient subjected to multiple dose adjustments. (c) Hemoglobin levels of patients with drug discontinuation.|
|Table 2. Predictors of thalidomide response among patients with β-thalassemia.|